Metraipolis › archive › dc_31688bce2fef

B-cell-driven relapse and anti-CD20 rescue therapy after Alemtuzumab in RRMS: case report and literature review — Europe PMC PMID:41583442

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41583442
DOI
10.3389/fimmu.2025.1710669
License (as archived)
solo-consultazione
Archived
2026-11-06T23:54:25.296Z
SHA-256 of the archived text
b3172545e9e31f3faffd3b7f38b890086cc53381b15661da9624137f51e7fdc4
Stable URL of this page
https://metraipolis.com/documento/dc_31688bce2fef

How to cite

B-cell-driven relapse and anti-CD20 rescue therapy after Alemtuzumab in RRMS: case report and literature review — Europe PMC PMID:41583442 — Europe PMC (en), https://europepmc.org/article/MED/41583442 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_31688bce2fef (Metraipolis archive dc_31688bce2fef, sha256 b3172545e9e31f3faffd3b7f38b890086cc53381b15661da9624137f51e7fdc4)
BibTeX
@misc{dc31688bce2fef,
  title = {B-cell-driven relapse and anti-CD20 rescue therapy after Alemtuzumab in RRMS: case report and literature review — Europe PMC PMID:41583442},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41583442},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_31688bce2fef; sha256 b3172545e9e31f3faffd3b7f38b890086cc53381b15661da9624137f51e7fdc4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41583442. Agents can read the archived copy with the MCP tool read_document.